SCHEMBL1978383

SCHEMBL1978383

CC[C@H]1NC(=O)N(c2ccc(Oc3ccc(C)c(OC(F)(F)F)c3)nc2)C1=O

nearest known ligand 0.34

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MCHR1 Q99705 6/20 0.34
GPR119 Q8TDV5 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
MAPK1 P28482 1/20 0.33
SCN9A Q15858 5/20 0.33
SCN10A Q9Y5Y9 2/20 0.33
SCN7A Q01118 1/20 0.33
KCNH2 Q12809 1/20 0.33
MMP13 P45452 2/20 0.32
DRD1 P21728 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939529 1.00 POLB (0.34) POLBL3MBTL1MCHR1GPR119NPSR1
SCHEMBL30939671 0.89 POLB (0.33) POLBL3MBTL1MCHR1NPSR1DRD1
SCHEMBL1978645 0.89 POLB (0.33) POLBL3MBTL1MCHR1NPSR1DRD1
SCHEMBL22026376 0.89 POLB (0.33) POLBL3MBTL1MCHR1NPSR1DRD1
SCHEMBL1981120 0.88 CHRM2 (0.34) POLBL3MBTL1GPR119NPSR1KCNH2
SCHEMBL1982377 0.88 DRD1 (0.38) POLBMCHR1NPSR1DRD1
SCHEMBL20567334 0.88 NPSR1 (0.39) POLBNPSR1MAPK1MMP13
SCHEMBL20599031 0.88 DRD1 (0.38) POLBMCHR1NPSR1DRD1
SCHEMBL1980580 0.88 DRD1 (0.38) POLBMCHR1NPSR1DRD1
SCHEMBL30939542 0.88 DRD1 (0.38) POLBMCHR1NPSR1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3386506-B1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LTD (GB) 2024-01-24 EP claimed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US claimed
US-20190000848-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2019-01-03 US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US claimed
EP-3386506-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN Autifony Therapeutics Limited (GB) 2018-10-17 EP claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US claimed
WO-2017098254-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2017-06-15 WO claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 POLB 4014/4885L3MBTL1 4332/4885MCHR1 1923/4885
US-20190000848-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 POLB 4505/4885L3MBTL1 3475/4885MCHR1 2317/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 POLB 4014/4885L3MBTL1 4332/4885MCHR1 1923/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 POLB 4014/4885L3MBTL1 4332/4885MCHR1 1923/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 POLB 4014/4885L3MBTL1 4332/4885MCHR1 1923/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 POLB 4014/4885L3MBTL1 4332/4885MCHR1 1923/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 POLB 4010/4885L3MBTL1 4300/4885MCHR1 1913/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 POLB 4542/4885L3MBTL1 3471/4885MCHR1 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.